Résumé
Objective:To study the effect of naoxintong capsules combined with nerve growth factor on the serum levels of interleukin-6 (IL-6),matrix metalloproteinase-9 (MMP-9) and S100B of patients with hypertensive intracerebral hemorrhage.Methods:88 patients with hypertensive intracerebral hemorrhage who were treated in our hospital from August 2015 to July 2016 were selected and randomly divided into the observation group and the control group The patients in the control group were treated with nerve growth factor,while the patients in the observation group were treated with naoxintong capsules combined with nerve growth factor.Then the clinical efficacy,GCS,GOS score,serum levels ofIL-6,MMP-9 and S100B were observed and compared between the two groups.Results:After treatment,the total effective rate in the observation group was significantly higher than that the control group (P＜0.05).After treatment,the GCS and GOS scores of the two groups were significantly higher than before,and the GCS and GOS of the observation group were higher than those of the control group (P＜0.05).After treatment,the serum levels of IL-6,MMP-9 and S100B in the two groups were significantly lower than before,and the observation group were lower than those of the control group (P＜0.05).There was adverse reactions in the two groups.Conclusion:Naoxintong capsule combined with nerve growth factor can reduce the serum levels of IL-6,MMP-9 and S100B in patients with hypertensive intracerebral hemorrhage,with obvious clinical curative effect and high safety.
Résumé
Bronchial asthma is a chronic airway inflammation disorder involving lymphocyte activation and various cytokines secretion by lymphocyte. The inflammatory response results from a complex network of interactions between inflammatory cells (mast cells, eosinophils, macrophages) and resident cells belonging to the lung structure itself like EC, fibroblasts, or bronchial epithelial cells. IL-6 which is known to up-regulate the endothelial cell expression of adhesion molecules participating in the development of the inflammatory reaction in bronchial asthma is produced by alveolar macrophage. ICAM-1 is produced by bronchial epithelial cell and expression by endothelial cell, which is known to enhance of the influx of various cells. RANTES which is known to a potent chemoattractant for eosinophils, lymphocytes, and monocytes, a member of the CC chemokine family, is expressed by bronchial epithelial cell. To evaluate whether markers of lymphocyte activation are useful markers of disease activity in bronchial asthma, we measured sIL-6, sICAM-1, sRANTES in 42 patients with mild to moderate bronchial asthma and in 26 normal controls and compared the result with other disease activity markers in asthma (pulmonary function, blood eosinophil counts). The mean level of sIL-6 was higher than that of normal control and correlated significantly with sICAM-1, FEV1% to predicted value. The mean level of sICAM-1 was higher than that of normal control and correlated significantly with FEV1%, FEV1% to predicted value. The mean level of sRANTES showed the tendency to be higher than that of normal control, but not significant statistically, and did not correlated with sIL-6, sICAM-1, FEV1%, FEV1% to predicted value, blood eosinophil counts. It appeared that sIL-6 and sICAM-1 could be a disease marker in bronchial asthma. But, clinical application of the measurement of these markers needs to be studied further.